Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Lymphoproliferative Disorders”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01660451
What this trial is testing

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Bayer 227
Not applicableStudy completedNCT01381705
What this trial is testing

Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

Who this might be right for
Lymphoma
ECOG-ACRIN Cancer Research Group 259
Testing effectiveness (Phase 2)Study completedNCT00875056
What this trial is testing

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Who this might be right for
Lymphoma
Merck Sharp & Dohme LLC 56
Very early researchStudy completedNCT02846935
What this trial is testing

P53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Who this might be right for
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's Lymphomas+1 more
Yogen Saunthararajah 7
Early research (Phase 1)Study completedNCT03424603
What this trial is testing

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Who this might be right for
B-cell LymphomaNon Hodgkin LymphomaMultiple Myeloma+5 more
Sutro Biopharma, Inc. 70
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Large-scale testing (Phase 3)Ended earlyNCT01732913
What this trial is testing

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Who this might be right for
Indolent Non-Hodgkin's Lymphomas
Gilead Sciences 295
Early research (Phase 1)UnknownNCT03823365
What this trial is testing

Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
A.O. Ospedale Papa Giovanni XXIII 19
Not applicableUnknownNCT05803395
What this trial is testing

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin LymphomaCOVID-19
Gruppo Italiano Malattie EMatologiche dell'Adulto 954
Testing effectiveness (Phase 2)Looking for participantsNCT06530550
What this trial is testing

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Who this might be right for
Lymphoma, T-CellNK-LGL LeukemiaT-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China 51
Testing effectiveness (Phase 2)Study completedNCT02362035
What this trial is testing

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Who this might be right for
Follicular Lymphoma (FL)CLLSmall Lymphocytic Lymphoma (SLL)+10 more
Acerta Pharma BV 161
Testing effectiveness (Phase 2)Ended earlyNCT02811679
What this trial is testing

Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Massachusetts General Hospital 13
Testing effectiveness (Phase 2)Ended earlyNCT02258529
What this trial is testing

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Who this might be right for
Follicular LymphomaSmall Lymphocytic Lymphoma
Gilead Sciences 10
Early research (Phase 1)Study completedNCT00005580
What this trial is testing

Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Virginia Commonwealth University 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT03147885
What this trial is testing

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Extranodal Marginal Zone Lymphoma+12 more
Barbara Ann Karmanos Cancer Institute 43
Large-scale testing (Phase 3)Study completedNCT01461928
What this trial is testing

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 692
Not applicableStudy completedNCT00574730
What this trial is testing

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
University of Nebraska 27
Testing effectiveness (Phase 2)Study completedNCT00868608
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Who this might be right for
Lymphoma
Pfizer 81
Large-scale testing (Phase 3)Ended earlyNCT01732926
What this trial is testing

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Who this might be right for
Indolent Non-Hodgkin's Lymphomas
Gilead Sciences 475
Testing effectiveness (Phase 2)Ended earlyNCT01799889
What this trial is testing

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more
Gilead Sciences 326
Next Page